1 Excellent Growth Stock to Buy Near Its 52-Week Low
The bear market we experienced last year was especially harsh. The otherwise high-flying but unprofitable growth-oriented companies that performed well during the pandemic (sometimes called "pandemic stocks") did not have a great year either. Telehealth specialist Teladoc (NYSE: TDOC) is a corporation at the intersection of these two categories, so it isn't surprising that its shares were hammered in 2022.
But there are excellent reasons to be a shareholder in Teladoc. The company could eventually turn things around and possibly deliver market-beating returns. Here is why this company is worth investing in, especially at its current levels.
Teladoc experienced a hard year in 2022, partly due to massive net losses associated with impairment charges linked to the company's acquisition of Livongo Health back in 2020. Even putting that aside, though, the company still isn't profitable. The company's net loss in the third quarter -- when it did not report significant impairment charges -- was $73.5 million, slightly better than the $84.3 million net loss reported during the year-ago period.
Source Fool.com
